180 Life Sciences Announces Publication of a Review on the Biological Basis of Dupuytren's Disease

Stock Information for 180 Life Sciences Corp.

Loading

Please wait while we load your information from QuoteMedia.

More Recent News About 180 Life Sciences Corp.

180 Life Sciences Regains Full Compliance with Nasdaq Minimum Bid Price Requirement
180 Life Sciences Corp. Announces 1-For 19 Reverse Stock Split as Part of Nasdaq Compliance Plan
180 Life Sciences Engages Financial Advisor to Explore Strategic Alternatives
180 Life Sciences Announces Review of Strategic Alternatives
180 Life Sciences Corp. Announces Closing of $3 Million Public Offering
180 Life Sciences Corp. Announces Pricing of $3 Million Public Offering
180 Life Sciences Announces an Agreement for a Clinical Pharmacology Study Testing a New Formulation of CBD for Enhanced Oral Uptake
180 Life Sciences Provides Update on Regulatory Approval Process in the UK and US for Dupuytren's Disease Treatment; Continues Consultations with the UK MHRA and Initiates a Type C Meeting Request With the US FDA

Market data content copyright © QuoteMedia. Data delayed at least 15 minutes unless otherwise indicated (view Delay Times for all exchanges). Filings and Fundamentals by Morningstar. Insiders by Morningstar (USA) and SEDI (CDN). Analyst ratings by Zacks. Terms of Use.